Author

T. Strandgaard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 4 Research Focus:differential expression· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:gene regulatory network inference· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:proteomics· 2

Frequent Co-Authors

L. Dyrskjot· 5 shared I. Nordentoft· 4 shared J. B. Jensen· 3 shared P. Lamy· 3 shared S. V. Lindskrog· 3 shared E. Christensen· 2 shared F. Prip· 2 shared K. Birkenkamp-Demtroder· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

L. Dyrskjot

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Low T cell diversity is associated with poor outcome in bladder cancer: a comprehensive longitudinal analysis of the T cell receptor repertoire

A. Kjaer, N. Kristjansdottir, R. I. Juul, I. Nordentoft, K. Birkenkamp-Demtroder, J. Ahrenfeldt, T. Strandgaard, D. Radif, D. Hodgson, C. Abbosh, H. J. Aerts, M. Agerbaek, J. B. Jensen, N. J. Birkbak, L. Dyrskjot

This study shows that low T cell receptor diversity in bladder cancer patients is linked to poor outcomes and identifies TCR diversity as a potential biomarker for treatment.

bioRxiv · May 30, 2024 · PreprintCancer Biology

Field cancerization impacts tumor development, T-cell exhaustion and clinical outcomes in bladder cancer

T. Strandgaard, I. Nordentoft, K. Birkenkamp-Demtroder, L. Salminen, F. Prip, J. Rasmussen, T. G. Andreasen, S. V. Lindskrog, E. Christensen, P. Lamy, M. Knudsen, T. Steiniche, J. B. Jensen, L. Dyrskjot

This study shows that field cancerization in bladder cancer is linked to worse outcomes, higher mutational burden, and T-cell exhaustion, with urinary tumor DNA levels reflecting disease status.

bioRxiv · Feb 20, 2023 · PreprintCancer Biology

Single nucleus and spatially resolved intra-tumor subtype heterogeneity in bladder cancer

S. V. Lindskrog, S. S. Schmokel, I. Nordentoft, P. Lamy, M. Knudsen, F. Prip, T. Strandgaard, J. B. Jensen, L. Dyrskjot

This study investigates intra-tumor subtype heterogeneity in bladder cancer using single nucleus RNA-sequencing and spatial transcriptomics, showing higher class 2a weight in bulk RNA-sequencing correlates with worse outcomes.

bioRxiv · Oct 27, 2022Cancer Biology

Elevated HLA-E and NKG2A as a consequence of chronic immune activation defines resistance to M. bovis BCG immunotherapy in Non-Muscle-Invasive Bladder Cancer

D. Ranti, Y.-S. Wang, J. Daza, C. Bieber, B. Salome, E. Merritt, J.-A. Cavallo, E. Hegewisch-Solloa, E. M. Mace, A. M. Farkas, S. Schroff, B. Lee, M. Tran, T. Strandgaard, S. V. Lindskrog, , A. Horowitz

The paper identifies elevated HLA-E and NKG2A as markers of resistance to BCG immunotherapy in NMIBC, linked to immune escape mechanisms.

bioRxiv · Mar 6, 2022 · PreprintImmunology

Mutational analysis of field cancerization in bladder cancer

T. Strandgaard, I. Nordentoft, P. Lamy, E. Christensen, M. Borg Houlberg Thomsen, J. Bjerggaard Jensen, L. Dyrskjot

The paper analyzes mutations in normal and tumor bladder tissues to study field cancerization, finding more mutations in normal tissue from multifocal disease patients and non-tumor-specific driver mutations.

bioRxiv · Jan 31, 2019Cancer Biology